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Abstract
As it becomes evident that single nucleotide polymorphisms (SNPs) in humans can create metabolic inefficiencies, it is
reasonable to ask if such SNPs influence dietary requirements. Epidemiologic studies that examine SNPs relative to risks
for diseases are common, but there are few examples of clinically sized nutrition studies that examine how SNPs influence
metabolism. Studies on how SNPs influence the dietary requirement for choline provide a model for how we might begin
examining the effects of SNPs on nutritional phenotypes using clinically sized studies (clinical nutrigenomics). Most men
and postmenopausal women develop liver or muscle dysfunction when deprived of dietary choline. More than one-half of
premenopausal women may be resistant to choline deficiency-induced organ dysfunction, because estrogen induces the
gene [phosphatidylethanolamine-N-methyltransferase (PEMT)] that catalyzes endogenous synthesis of phosphatidylcho-
line, which can subsequently yield choline. Those premenopausal women that do require a dietary source of choline have a
SNP in PEMT, making them unresponsive to estrogen induction of PEMT. It is important to recognize differences in dietary
requirements for choline in women, because during pregnancy, maternal dietary choline modulates fetal brain
development in rodent models. Because choline metabolism and folate metabolism intersect at the methylation of
homocysteine, manipulations that limit folate availability also increase the use of choline as a methyl donor. People with a
SNPs inMTHFD1 (a gene of folate metabolism that controls the use of folate as a methyl donor) are more likely to develop
organ dysfunction when deprived of choline; their dietary requirement is increased because of increased need for choline
as a methyl donor. J. Nutr. 141: 531–534, 2011.
Introduction
The study of how nutrients interact with genes and how genes
influence metabolism, nutrigenomics, is a rapidly developing
new discipline within nutrition. Genome-wide association stud-
ies (GWAS), in which many thousands of people’s genetic
variations are associated with a risk for a disease, are at the
cutting edge of nutrition epidemiology research. These studies
are usually observational and collect limited biological data
about the persons studied. As it becomes evident that single
nucleotide polymorphisms (SNPs; a nucleotide alteration that
occurs in.1% of the population and is inherited) in humans can
create metabolic inefficiencies, it is reasonable to ask if such
SNPs influence dietary requirements. To date, few studies exist
in which fewer numbers of humans have been more intensively
characterized by measuring SNPs and nutritionally relevant
clinical outcomes (clinical nutrigenomics). Though such studies
may eventually enable clinicians to provide personalized nutrit-
ion recommendations, in the immediate future, it is this type of
study that can help define the role of genetic variation in
influencing diet requirements. Currently, nutritionists estimate
the average nutrient requirements for a population assuming
that the dose-response curve for the effects of a nutrient are
normally distributed among the population and thus do not
consider that there might be multiple and separate dose-response
curves. This can result in recommendations for dietary intake
that are hard to achieve by eating foods. Once it is possible to
identify the sources of metabolic variation, subgroups that differ
in nutrient requirements will be identified, interventions can
then be targeted, and dietary recommendations refined.
It is not uncommon in nutrition research to find a nutrient-
health association in one study and subsequently not observe
this relationship (or even observe an inverse relationship) in
another study. In nutrition research studies, when a large
variance exists in response to a nutrient, statistical analyses
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often argue for a null effect. In part, this problem is due to large
variance around the mean in the population studied. This
variance is not only due to random biological noise, but also to
inclusion of genetically definable subpopulations with widely
differing responses to the nutrient. If responders could be
differentiated from nonresponders based on nutrigenomic pro-
filing, this statistical noise could be eliminated and the sensitivity
(reproducibility) of nutrition research could be greatly increased.
This approach was recently reviewed (1,2).
Developing clinical nutrigenomics
The use of genome-wide profiling of common SNPs to identify
genetically different subpopulations that have differential risks
for disease has become common. For genes that exert small
effects on a disease process, a gene variant adds only a small
amount of increased risk, often difficult to distinguish from
background variation. In GWAS, it is common to measure
millions of SNPs in thousands of participants, thereby making a
very large number of comparisons and increasing the opportu-
nity for false discovery. For this reason, more stringent defini-
tions of significance are used in GWAS [e.g. require a P , 5 3
1027 (3)]. Using thousands of participants in a nutrition study is
practical if the nutrition effect on phenotype is easily measured
(e.g. a simple blood measurement), but studies using this many
participants are impossible if assessment of phenotype requires
expensive or invasive methods (e.g. MRI or glucose clamps). If
the same stringent P-values were required in clinically sized
nutrition studies, these studies would detect a significant
difference only if the effect of the nutrient was very large.
However, there are designs for examining the effects of SNPs on
nutrient requirements that permit the use of less stringent
thresholds for significance of P-values than those thresholds used
for the GWAS-type design.
The important elements of a clinically sized SNP study have
already have been considered by the same scientific panel that
suggested the stringent thresholds for P-values used in GWAS-
type studies (3). Clinically sized studies on SNPs and nutrient
metabolism need to select a priori a small number of targeted
SNPs based on knowledge of the underlying processes causing
the phenotype (e.g. selecting a gene in the metabolic pathway of
a nutrient), SNPs for which there is credible laboratory evidence
that they alter metabolism of the nutrient, or SNPs that are likely
to result in defective protein products (such as nonsynonymous
coding SNPs) (3). Because the number of SNP-phenotype
comparisons is limited by this study design, correction for false
discovery becomes less problematic. By sharpening the focus of
the study, it is possible to accept a less rigorous P-value; however,
creating a credible biological hypothesis post hoc is not
acceptable (3). Effect size is still an important issue, for a
clinically-sized study to be adequately powered the size of the
effect of the SNP on nutrient requirement must be large enough,
and consistent enough, to stand out from noise created by
individual variation; unknown confounding factors are less
likely to produce such large effects (3). Finally, replication of the
association between SNP and phenotype in an independent
study is important.
The observation of an association between a SNP and a
nutritional phenotype or disease risk does not mean that the
identified SNPs is the cause of the metabolic inefficiency. A SNP
is part of a grouping of SNPs (haplotype) that are inherited
together; thus, it could be one of the other linked SNPs that is
functionally important. However, a SNP that is related to a
nutritional phenotype still can be a very useful biomarker that is
predictive of the metabolic inefficiency.
Nutrigenomics also considers transcription factors
and epigenetics
Nutrigenomics/nutrigenetics involves more than the study of
gene polymorphisms. Other mechanisms can influence gene
expression and are relevant to nutrition. Transcription factors
are molecules that bind to response elements and then activate or
inhibit gene expression, sometimes thereby altering metabolism.
An example discussed later is the effect of estrogen (bound to
estrogen receptor complex) on the gene for endogenous biosyn-
thesis of phosphatidylcholine, the route for endogenous biosyn-
thesis of choline.
Nutrients also influence the epigenetic marking of DNA,
thereby altering gene expression [reviewed in (1,4)]. People all
share a great deal of genetic code in common and yet can differ
greatly in metabolism and other phenotypes. Some of the
variation between individuals is due to genetic differences, as
discussed earlier. However, even monozygous twins can be
metabolically different despite having identical genetic codes (5).
Obviously, metabolic phenotype must be determined by more
information than that encoded in DNA sequence alone. In part,
it is due to another coding system, the epigenetic code (6). This
epigenetic code is a series of marks added to DNA or to the
proteins (histones) around which DNA is wrapped. The best
understood marks are DNA methylation, but covalent modifi-
cations of histones and chromatin, and RNA interference also
mediate epigenetic regulation of gene expression (7). An
example discussed below is the effect of choline, a major methyl
donor, on epigenetic marking of genes.
Clinically sized nutrigenomic studies identifying
the dietary requirement for choline
Studies on how SNPs influence the dietary requirement for
choline provide a model for how we might begin to examining
the effects of SNPs on nutritional phenotypes using clinically
sized studies (clinical nutrigenomics).
Choline metabolism has been reviewed in detail elsewhere
(8). Choline is used to make acetylcholine (a neurotransmitter)
and phospholipids (phosphatidylcholine and sphingomyelin,
among the most important), or it is irreversibly oxidized to form
betaine (8). Betaine is a methyl donor for the conversion of
homocysteine to methionine (8). This is the precursor for the
synthesis of S-adenosylmethionine, the universal methyl donor
needed for methylation of DNA, RNA, and proteins. As a
methyl donor, choline’s metabolism is highly related to the
metabolism of other methyl donors such as methyl-folate and
methionine, and manipulations that alter metabolism of any 1 of
these 3 result in changes in metabolism of the other 2 methyl
donors (8). Thus, an integrated approach is needed when
determining the dietary requirement for these 3 nutrients.
A database is available that describes the choline and betaine
content of foods (9). Nutritionists have been discouraging intake
of many of the foods that are highest in choline, because they are
also high in fat and cholesterol (e.g. eggs and liver), and the 2005
NHANES survey found that only a small percent of the
population achieves the recommended adequate intake for
choline (10). The only source of choline other than diet is
from the de novo biosynthesis of phosphatidylcholine (can be
converted to choline) catalyzed by phosphatidylethanolamine-
N-methyltransferase (PEMT) in liver (11). Studies in humans
show that dietary choline is required [reviewed in (8)]. The
United States has established for choline an adequate intake level
(;0.5 g/d) and a tolerable upper intake limit value (3.5 g/d) for
adults (12).
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The study of the gene-nutrient interactions that modulate the
dietary requirement for choline (13–16) provides interesting
insights into useful designs for clinically sized nutrigenomic
studies. The outcome markers used for this study assessed
susceptibility to developing organ (liver and muscle) dysfunction
when fed a low-choline diet under controlled conditions. Study
participants were fed a standard diet containing a known
amount of choline [550 mg×(70 kg×d21); baseline]. On d 11
participants were switched to a diet containing ,50 mg/d
choline for up to 42 d. If at some point during the depletion
period the participants developed organ dysfunction associated
with choline deficiency, they were switched to a diet containing
choline until repletion. Most men and postmenopausal women,
but only 44% of premenopausal women, fed low-choline diets
developed reversible fatty liver (measured by mass resonance
spectroscopy) as well as liver and muscle damage (16). This
difference in dietary choline requirement for young women
occurs, because they have an estrogen-enhanced capacity for
producing their own choline; the PEMT gene (forms phospha-
tidylcholine) is induced by estrogen in human hepatocytes, with
maximal activation at estrogen concentrations reached at term
in pregnancy (17). Thus, capacity for this endogenous source of
choline is highest during the period when females need to
support fetal development. This is important, because the
demand for choline is very high during pregnancy and lactation
(18) and, as discussed later, choline is critical for normal fetal
development.
Though more than one-half of premenopausal women were
resistant to choline deficiency-induced organ dysfunction, those
premenopausal women that did require a dietary source of
choline had a SNP in PEMT (rs12325817; 74% of women in
North Carolina had 1 or more variant alleles), making them
unresponsive to estrogen induction of PEMT (19,20). This
common SNP greatly increased the risk for developing organ
dysfunction when participants were fed a low-choline diet (OR =
2; P , 0.00005, based on 64 women studied) (20). We noted
earlier that choline and folate metabolism are highly related.
Premenopausal women with a SNP in the geneMTHFD1 (5,10-
methylenetetrahydrofolate dehydrogenase 1; rs2236225) were
15 times more likely to develop signs of choline deficiency (P ,
0.0001) on the low-choline diet than were the wild types (21).
Sixty-three percent of our study population had at least 1 allele
for this SNP in 5,10-methylenetetrahydrofolate dehydrogenase,
which alters the availability of 5-methyl tetrahydrofolate for
homocysteine remethylation, increasing the use of choline-
derived methyl groups to remove homocysteine.
Choline, epigenetics, and neural development
Dietary choline (as well as folate) is used to formmethionine and
thereafter S-adenosylmethionine (the methyl donor for DNA
and histone methylation). Thus, it is to be expected that diet
during pregnancy influences the epigenetic status of the devel-
oping fetal brain. In rats and mice, maternal dietary choline
intake has an important effect on neurogenesis (22) and angio-
genesis (23). A maternal diet low in choline decreased both
processes in the fetal hippocampus and increased apoptosis in
this area of fetal brain (22,24,25). One of the mechanisms
identified that explains this effect was a marked change in the
epigenetic marks present in fetal brain (23,26). Global DNA
methylation decreased in the neuroepithelial layer of the
hippocampus in fetal brains from pregnant rodent dams fed a
low-choline diet and, specifically, the gene encoding cyclin-
dependent kinase (Cdkn3) was hypomethylated in its promoter
(26,27). This hypomethylation resulted in increased gene
expression and increased downstream signaling that resulted in
decreased cell cycling (26), consistent with decreased neuro-
genesis. Similarly, genes regulating angiogenesis were hypome-
thylated and overexpressed, resulting in fewer blood vessels in
fetal brain (23).
These changes in fetal brain structure that are caused by
changing maternal intake of choline during pregnancy have
long-lasting effects that alter brain function throughout life,
including long-lasting changes in the hippocampal function
(memory) of the adult offspring. Choline supplementation of
pregnant rats enhanced memory in their offspring and this
improvement lasted until they were old animals (28–30). It
also enhanced an electrical property of the hippocampus called
long-term potentiation (31,32), which is normally positively
associated with memory. The offspring from mothers fed a
choline-deficient diet manifested opposite outcomes (28,33).
Does this work in rodents apply to humans?
We do not know if these effects on brain development described
in rodent models apply to humans, because no comparable
studies have yet been performed. One study in humans observed
that cord blood choline concentrations were not related to
intelligence quotient at 5 y (34), but this study used relatively
crude measures of intelligence and cord blood choline is not
necessarily a good biomarker for maternal intake of choline.
Despite the dearth of human data on choline and brain
development, the similarities between rodent and human
hippocampal development are enough that there is reason to
be concerned that the 2005 NHANES data suggest that most
pregnant women do not consume adequate amounts of choline
(10), and case-control studies in California suggest that women
eating lower choline diets are at increased risk for giving birth to
babies with neural tube defects (35) and cleft palate. In addition,
because approximately one-half of the population has gene
polymorphisms that affect choline and folate metabolism (20), it
is likely that different individuals may have different dietary
requirements for choline and may need to pay special attention
to choline intake during pregnancy.
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